Anti-oxidative Effect of Fluvastatin in Hyperlipidemic Type 2 Diabetic Patients

Endocrine Journal

Ryuzo KAWAMORI¹  Shinnya MIWA¹  Hirotaka WATADA¹  Chie OMURA¹  Kyoko NISHIYAMA¹  Tomio ONUMA¹  Yasushi TANAKA¹  Naoko TAKAYANAGI¹ 

[1] Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine

关键词: Oxidative stress;    HMG-CoA reductase inhibitor;    Type 2 diabetes;   

DOI  :  10.1507/endocrj.52.259

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

References(19)Cited-By(11)An open-label prospective cross-over trial was performed to evaluate the antioxidative effect of fluvastatin in Japanese type 2 diabetics with hyperlipidemia. The study subjects were 10 patients who were on pravastatin (10 mg/day) or simvastatin (5 mg/day). After at least 12 weeks of continuous pravastatin or simvastatin therapy, the drugs were washed out for 12 weeks and replaced with fluvastatin (30 mg/day), then the treatment was continued for another 12 weeks. Total cholesterol and LDL cholesterol were efficiently and comparably reduced by all three statin agents. There were no differences in serum parameters of oxidative stress such as malondialdehyde-modified low-density lipoprotein, thiobarbituric acid-reactive substances, and 8-iso-prostaglandin F2α between pravastatin/simvastatin and fluvastatin. However, fluvastatin, but not pravastatin/simvastatin, significantly reduced 3,5,7-cholestatriene in erythrocyte membrane, representing the extent of membrane cholesterol peroxidation. Our data demonstrated that fluvastatin has a unique anti-oxidative effect in patients with type 2 diabetes and hyperlipidemia, compared with other statins.

【 授权许可】

Unknown